JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Omnicell (NASDAQ:OMCL) Stock

Omnicell (NASDAQ:OMCL) had its target price increased by JPMorgan Chase & Co. from $37.00 to $44.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other equities analysts have also weighed in on OMCL. Bank of America restated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays increased their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company increased their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and an average price target of $52.00.

Omnicell Stock Performance

Omnicell stock traded down $0.51 during trading hours on Thursday, hitting $43.60. 33,248 shares of the stock were exchanged, compared to its average volume of 536,197. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74. The business’s 50-day moving average is $44.22 and its two-hundred day moving average is $37.25. The stock has a market capitalization of $2.02 billion, a P/E ratio of -113.10, a P/E/G ratio of 35.67 and a beta of 0.81.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the last quarter. 1620 Investment Advisors Inc. grew its holdings in Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the last quarter. EntryPoint Capital LLC grew its holdings in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after acquiring an additional 1,345 shares during the last quarter. Finally, CWM LLC grew its holdings in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.